Cellavita HD Higher dose ( DrugBank: - )

1 disease
IDDisease name (Link within this page)Number of trials
8Huntington disease2

8. Huntington disease

Clinical trials : 242 /  Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03252535
(ClinicalTrials.gov)		January 15, 201815/8/2017Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's DiseaseDose-Response Evaluation of the Investigational Product Cellavita HD After Intravenous Administration in Patients With Huntington's DiseaseHuntington DiseaseBiological: Cellavita HD lower dose;Biological: Cellavita HD higher dose;Other: PlaceboAzidus BrasilCellavita Pesquisa Científica LtdaCompleted21 Years65 YearsAll35Phase 2Brazil
2NCT02728115
(ClinicalTrials.gov)		October 16, 201711/3/2016Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's DiseaseFirst in Human Study to Evaluate Safety of Cellavita HD Investigational Product After Intravenous Application in Participants With Huntington's DiseaseHuntington DiseaseBiological: Cellavita HD Lower Dose;Biological: Cellavita HD Higher doseAzidus BrasilCellavita Pesquisa Científica Ltda;Azidus Brasil Scientific Research and Development LtdaActive, not recruiting21 Years65 YearsMale6Phase 1Brazil